596 results on '"Hurt, Aeron C"'
Search Results
52. Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection
53. Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility
54. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014
55. Overview of the 3rd isirv-Antiviral Group Conference – advances in clinical management
56. Detection of influenza A H1N1 and H3N2 mutations conferring resistance to oseltamivir using rolling circle amplification
57. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013
58. Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact
59. Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model
60. Reassortment and Persistence of Influenza A Viruses from Diverse Geographic Origins within Australian Wild Birds: Evidence from a Small, Isolated Population of Ruddy Turnstones
61. Neutralizing Antibody Therapeutics for COVID-19
62. Predicting potentially permissive substitutions that improve the fitness of A(H1N1)pdm09 viruses bearing the H275Y NA substitution
63. Understanding the Impact of Resistance to Influenza Antivirals
64. Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses
65. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses
66. Surveillance and analysis of avian influenza viruses, Australia
67. Influenza virus transmission from horses to dogs, Australia
68. Oseltamivir Resistance and the H274Y Neuraminidase Mutation in Seasonal, Pandemic and Highly Pathogenic Influenza Viruses
69. Peramivir and laninamivir susceptibility of circulating influenza A and B viruses
70. Burden of influenza B virus infection and considerations for clinical management
71. Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses
72. Second isirv antiviral group conference: overview
73. The significance of increased influenza notifications during spring and summer of 2010–11 in Australia
74. Progressive emergence of an oseltamivir-resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient
75. A COVID-19 transmission model informing medication development and supply chain needs
76. Performance of six influenza rapid tests in detecting human influenza in clinical specimens
77. Influenza and COVID‐19: What does co‐existence mean?
78. Cover
79. Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model
80. In-concert immune dynamics during natural influenza virus infection and recovery in acute hospitalized patients
81. The Fluorescence Neuraminidase Inhibition Assay: A Functional Method for Detection of Influenza Virus Resistance to the Neuraminidase Inhibitors
82. The Chemiluminescent Neuraminidase Inhibition Assay: A Functional Method for Detection of Influenza Virus Resistance to the Neuraminidase Inhibitors
83. Seroprevalence of Seasonal and Pandemic Influenza A in Kuala Lumpur, Malaysia in 2008–2010
84. Influenza antiviral resistance in the Asia-Pacific region during 2011
85. Influenza antivirals and resistance: the next 10 years?
86. Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment.
87. Infection with different human influenza A subtypes affects the period of susceptibility to secondary bacterial infections in ferrets.
88. Community Transmission of Oseltamivir-Resistant A(H1N1)pdm09 Influenza
89. Host age shapes virome abundance and diversity in birds
90. Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir
91. Viral burden, inflammatory milieu and CD8 + T‐cell responses to influenza virus in a second‐generation thiazolide (RM‐5061) and oseltamivir combination therapy study
92. Utilising animal models to evaluate oseltamivir efficacy against influenza A and B viruses with reduced in vitro susceptibility
93. Sequencing B cell receptors from ferrets (Mustela putorius furo)
94. Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission
95. Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy
96. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017–2018
97. A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions
98. Sustained virome diversity in Antarctic penguins and their ticks: geographical connectedness and no evidence for low pathogen pressure
99. The evolution and genetic diversity of avian influenza A(H9N2) viruses in Cambodia, 2015 – 2016
100. Avian influenza in the Greater Mekong Subregion, 2003–2018
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.